Work

PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.13

Authors: Johann S. De Bono, Christopher Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N. Chi, David Olmos, Shahneen Kaur Sandhu, Christophe Massard, Nobuaki Matsubara, Josep Garcia, Malgorzata Nowicka, Matthew Wongchenko, Zhen Shi

Institutions: Institute of Cancer Research, Royal Marsden Hospital, Dana-Farber Cancer Institute, Azienda Ospedaliera S.Maria, Weill Cornell Medicine, BC Cancer Agency, Spanish National Cancer Research Centre, Peter MacCallum Cancer Centre, Institut Gustave Roussy, National Cancer Center Hospital East, F. Hoffmann-La Roche AG, Genentech

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3135328828

Cites:

Cited by: 25

Related to: 10